Filippos Koutroumpakis

Filippos Koutroumpakis

Auto-generated profile, based on publicly available information

Filippos Koutroumpakis

Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in Journal of the Academy of Nutrition and Dietetics
Verified
Journal Article
Closed access
MAMaaz Ahsan
Maaz Ahsan
FKFilippos Koutroumpakis
Filippos Koutroumpakis
CRClaudia Ramos Rivers
Claudia Ramos Rivers
AWAnnette S. Wilson
Annette S. Wilson
EJElyse Johnston
Elyse Johnston
DBDavid G. Binion
David G. Binion

21 January 2020 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
KPKrishnapriya Marangattu Prathapan
Krishnapriya Marangattu Prathapan
CRClaudia Ramos Rivers
Claudia Ramos Rivers
AAAlyce Anderson
Alyce Anderson
FKFilippos Koutroumpakis
Filippos Koutroumpakis
IKIoannis Koutroubakis
Ioannis Koutroubakis
DBDavid G Binion
David G Binion
Peripheral blood eosinophilia (PBE) is a biomarker of an aggressive multiyear natural history in adults with inflammatory bowel diseases (IBDs). Additionally, PBE at diagnosis is associated with higher disease activity in pediatric-onset IBD. We sought to determine if PBE can function as a biomarker of long-term disease severity in pediatric-onset IBD patients who are followed into adulthood. We analyzed a consented, prospective, natural history IBD registry at an adult tertiary center from 2009 to 2018. Prevalence of PBE was evaluated in both pediatric- and adult-onset IBD patients. Demographics, clinical characteristics, and health care utilization data were compared in patients with and without PBE. Among 2800 adult IBD patients, 23.4% had pediatric-onset disease. PBE was found in 34% of the pediatric-onset patients compared with 26.8% of the adult-onset IBD patients (P < 0.001). In the pediatric-onset IBD cohort, PBE was associated with higher rates of allergies (P < 0.0001), but not of asthma, allergic rhinitis, or primary sclerosing cholangitis. In the adult IBD patients with pediatric-onset disease, PBE was associated with higher rates of C-reactive protein elevation (P < 0.0001), erythrocyte sedimentation rate elevation (P < 0.0001), higher health care utilization, and higher average health care charges per year (P < 0.00001). Peripheral blood eosinophilia was more prevalent in adult IBD patients with pediatric-onset compared with adult-onset disease. Among all IBD patients with long-term follow-up, PBE defined a subgroup with more severe illness. These data suggest that PBE may be a biomarker for a high-risk subgroup with high cost trajectory and long-term severity in pediatric-onset IBD that persists into adulthood.

3 September 2020 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
FKFilippos Koutroumpakis
Filippos Koutroumpakis
APAnna Evans Phillips
Anna Evans Phillips
DYDhiraj Yadav
Dhiraj Yadav
JMJorge D Machicado
Jorge D Machicado
MAMaaz Ahsan
Maaz Ahsan
DBDavid G Binion
David G Binion
Immunoglobulin G subclass 4 (IgG4) is hypothesized to play an immunomodulatory role, downregulating humoral immune responses. The role of this anti-inflammatory molecule in inflammatory bowel disease (IBD) has not been fully characterized. We sought to define alterations in serum IgG4 in patients with IBD and their association with multiyear disease severity. We analyzed metadata derived from curated electronic health records from consented patients with IBD prospectively followed at a tertiary center over a 10-year time period. Patients with IBD with IgG4 serum levels available formed the study population. Demographics and multiyear clinical data were collected and analyzed. We stratified patients with IBD with low, normal, or high serum IgG4 levels. We found IgG4 characterized in 1193 patients with IBD and low IgG4 levels in 233 patients (20%) and elevated IgG4 levels in 61 patients (5%). An IgG4 deficiency did not significantly correlate with other antibody deficiencies. In a multiple Poisson regression analysis, low IgG4 was associated with more years on biologic agents (P = 0.002) and steroids (P = 0.049) and more hospital admissions (P < 0.001), clinic visits (P = 0.010), outpatient antibiotic prescriptions (P < 0.001), and CD-related surgeries (P = 0.011) during the study period after controlling for certain confounders. Elevated IgG4 was only associated with primary sclerosing cholangitis (P = 0.011). A cohort of patients with IgG4-deficient severe IBD received intravenous Ig replacement therapy, which benefited and was continued in 10 out of 11 individuals. An IgG4 subclass deficiency, distinct from other antibody deficiencies, occurred commonly in a referral IBD population and was associated with multiple markers of disease severity. This is the first association of IgG4 subclass deficiency with an inflammatory disease process. Further work is needed to define the mechanistic role of IgG4 deficiency in this severe IBD subgroup.

20 April 2020 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
FKFilippos Koutroumpakis
Filippos Koutroumpakis
MLMaham Lodhi
Maham Lodhi
MAMaaz Ahsan
Maaz Ahsan
CRClaudia Ramos Rivers
Claudia Ramos Rivers
MSMarc Schwartz
Marc Schwartz
DBDavid G Binion
David G Binion
Cholecystectomy (CCY) is one of the most frequently performed abdominal surgeries. However, the impact of CCY in clinical settings with altered gastrointestinal physiology and anatomy, such as Crohn’s disease (CD), has not been fully characterized. We sought to investigate clinical outcomes, disease severity, and quality of life of CD patients after CCY. We utilized a prospective, longitudinal registry of consented CD patients followed at a tertiary center. Crohn’s disease patients that had or had not undergone CCY formed the 2 study groups. The absence or presence of gallbladder was confirmed with abdominal CT scans obtained during routine care. Multiyear clinical, biochemical, and histologic data were collected and analyzed. Among 834 CD patients, 151 (18%) had undergone CCY. History of CCY was associated with higher disease activity (median Harvey-Bradshaw index; P < 0.001), more years with anemia (P = 0.048), lower albumin (P = 0.001), worse quality of life (mean Short Inflammatory Bowel Disease Questionnaire; P < 0.001), chronic abdominal pain (P < 0.001), higher risk for incident colonic dysplasia (P = 0.011), higher rates of annual hospital admissions (P = 0.004), and opioid use (P < 0.001). In multivariate analysis, CCY remained associated with higher disease activity (P < 0.001), lower albumin (P = 0.008), lower quality of life (P < 0.001), and more hospital admissions (P = 0.008), whereas CD patients with diseased ileum had higher risk for colonic dysplasia (P = 0.031). CCY in CD patients was associated with multiple markers of disease activity and worse quality of life during multiyear follow up. This data suggests that CCY in CD patients may adversely impact the long-term clinical course.

9 August 2020 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
MKMichael Kurin
Michael Kurin
AAAlyce Anderson
Alyce Anderson
CRClaudia Ramos Rivers
Claudia Ramos Rivers
FKFilippos Koutroumpakis
Filippos Koutroumpakis
PCPatricia Centa
Patricia Centa
DBDavid G. Binion
David G. Binion